Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 1

Status

Completed 4

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 84Breast 82Lymphoid 22Other solid neoplasm 9Gynecologic 9Genitourinary 9CNS 6Sarcoma 5Other hematologic neoplasm 5Plasma cell 4Gastrointestinal 4Dermatologic 3Endocrine 2Tumor-Agnostic 1NET 1

Conditions

Multiple Myeloma 4Neoplasms, Plasma Cell 1Leukemia 1Amyloidosis 1

Interventions

Dexamethasone 393Bortezomib 246Lenalidomide 222Cyclophosphamide 184Melphalan 168Calcium Dobesilate 119Peripheral Blood Stem Cell Transplantation 94fludarabine phosphate 89Thalidomide 82Filgrastim 74carfilzomib 70pomalidomide 68Granulocyte Colony-Stimulating Factor 63Busulfan 63Mycophenolic Acid 61daratumumab 58Whole-Body Irradiation 57ixazomib 54fludarabine 52Tacrolimus 52Prednisone 51Cyclosporine 50Antilymphocyte Serum 35dexamethasone acetate 32plerixafor 30Etoposide 30Methotrexate 29Radiotherapy 28dexamethasone 21-phosphate 27Doxorubicin 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × Vinorelbine × Plasma cell × Clear all
NCT03442673 2025-03-28

MOCCCA

Insel Gruppe AG, University Hospital Bern

Phase 2 Completed
137 enrolled
Plasma cell

Multiple Myeloma

NCT02791373 2018-04-03

ViGeM

Insel Gruppe AG, University Hospital Bern

Phase 2 Completed
136 enrolled
Plasma cell

Amyloidosis, Multiple Myeloma

NCT00477035 2017-01-11

Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies

Stanford University

Phase 1 Completed
22 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Multiple Myeloma

NCT01220375 2014-04-17

PAV

Insel Gruppe AG, University Hospital Bern

Phase 2 Completed
44 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡